Lactic Acidosis

Richard D. Moore, M.D.
Lactic Acidosis is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

COVID-19 Update with Dr. Paul Auwaerter of Johns Hopkins : Omicron Variant, Testing, and TreatmentCOVID-19 Update with Dr. Paul Auwaerter of Johns Hopkins : Omicron Variant, Testing, and Treatment

Coronavirus COVID-19 (SARS-CoV-2)Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 PandemicSuicide Risk in the COVID-19 Pandemic

Moderna COVID-19 VaccineModerna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 VaccineJohnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

CLINICAL

  • Symptoms: Fatigue, weakness, myalgias, and GI distress, including abdominal pain, abdominal distention, nausea/vomiting, diarrhea. Later can advance to dyspnea, orthostasis, organ failure (hepatic, renal), cardiovascular collapse and death.
  • Mortality: 7% with lactate 5-10 mM, 20-30% with lactate 10-15 mM, 50-60% with lactate >15 mM
  • Caused by NRTI use: d4T, ddI, AZT. Does not appear to be caused by 3TC, FTC, ABC, TDF, TAF, though listed in package insert as a class effect. Use of d4T and ddI no longer recommended; occurrence now rare.
  • Associated with mitochondrial DNA gamma polymerase inhibition and decrease in mitochondrial DNA
  • May be accompanied by hepatic steatosis (fatty liver), pancreatitis. Fatal liver failure can occur (earliest reports in AZT-treated patients)
  • Increased risk with lower CD4, older age, female sex.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

CLINICAL

  • Symptoms: Fatigue, weakness, myalgias, and GI distress, including abdominal pain, abdominal distention, nausea/vomiting, diarrhea. Later can advance to dyspnea, orthostasis, organ failure (hepatic, renal), cardiovascular collapse and death.
  • Mortality: 7% with lactate 5-10 mM, 20-30% with lactate 10-15 mM, 50-60% with lactate >15 mM
  • Caused by NRTI use: d4T, ddI, AZT. Does not appear to be caused by 3TC, FTC, ABC, TDF, TAF, though listed in package insert as a class effect. Use of d4T and ddI no longer recommended; occurrence now rare.
  • Associated with mitochondrial DNA gamma polymerase inhibition and decrease in mitochondrial DNA
  • May be accompanied by hepatic steatosis (fatty liver), pancreatitis. Fatal liver failure can occur (earliest reports in AZT-treated patients)
  • Increased risk with lower CD4, older age, female sex.

There's more to see -- the rest of this entry is available only to subscribers.

© 2000–2022 Unbound Medicine, Inc. All rights reserved